TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 0.57%253.9B | -0.80%168.08B | 0.70%87.65B | -0.42%343.07B | 0.79%252.47B | 2.33%169.44B | 3.74%87.04B | 2.65%344.53B | 7.53%250.49B | 15.00%165.58B |
Operating income | 0.57%253.9B | -0.80%168.08B | 0.70%87.65B | -0.42%343.07B | 0.79%252.47B | 2.33%169.44B | 3.74%87.04B | 2.65%344.53B | 7.53%250.49B | 15.00%165.58B |
Cost of sales | -2.45%-176.39B | -3.24%-117.85B | -4.69%-60.46B | -2.61%-232.54B | -7.01%-172.18B | -7.00%-114.14B | -6.56%-57.76B | 5.50%-226.62B | 3.70%-160.9B | -3.79%-106.68B |
Operating expenses | -2.45%-176.39B | -3.24%-117.85B | -4.69%-60.46B | -2.61%-232.54B | -7.01%-172.18B | -7.00%-114.14B | -6.56%-57.76B | 5.50%-226.62B | 3.70%-160.9B | -3.79%-106.68B |
Gross profit | -3.46%77.51B | -9.16%50.23B | -7.18%27.18B | -6.25%110.54B | -10.38%80.29B | -6.12%55.3B | -1.40%29.29B | 23.03%117.91B | 36.00%89.59B | 42.96%58.9B |
Selling expenses | -10.16%-336M | -6.90%-217M | -9.09%-108M | -3.66%-425M | 33.41%-305M | 38.11%-203M | 32.19%-99M | 29.43%-410M | -11.98%-458M | 0.30%-328M |
Administrative expenses | -1.04%-6.96B | -3.28%-4.73B | -13.93%-2.43B | 1.19%-9.81B | -1.86%-6.89B | -0.11%-4.58B | -10.70%-2.13B | -8.89%-9.93B | -19.27%-6.77B | -27.58%-4.58B |
Research and development expenses | -24.37%-1.74B | -36.16%-979M | -13.22%-274M | 19.21%-3.01B | 13.48%-1.4B | -2.28%-719M | 27.76%-242M | -48.94%-3.72B | -101.12%-1.62B | -49.26%-703M |
Impairment and provision | 277.78%16M | 200.00%9M | 257.14%11M | 78.68%-285M | -111.11%-9M | -96.10%3M | -135.00%-7M | 47.79%-1.34B | 102.50%81M | 352.94%77M |
-Other impairment is provision | 277.78%16M | 200.00%9M | 257.14%11M | 78.68%-285M | -111.11%-9M | -96.10%3M | -135.00%-7M | 47.79%-1.34B | 102.50%81M | 352.94%77M |
Operating interest expense | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---2.17B | -9.85%-1.2B |
Special items of operating profit | -71.52%135M | -82.48%92M | -910.13%-640M | -73.32%-7.31B | -84.90%474M | -77.03%525M | -92.32%79M | -418.01%-4.22B | 43.51%3.14B | 36.97%2.29B |
Operating profit | -4.90%68.62B | -11.76%44.41B | -11.68%23.74B | -8.75%89.69B | -11.79%72.16B | -7.59%50.32B | -3.05%26.89B | 23.14%98.29B | 33.63%81.81B | 45.58%54.46B |
Financing income | 5.57%2.14B | 1.12%1.45B | 8.61%694M | -14.23%2.63B | --2.03B | --1.43B | --639M | --3.07B | ---- | ---- |
Financing cost | 1.09%-2.27B | -15.96%-1.48B | -4.57%-710M | 20.69%-3.12B | ---2.3B | ---1.27B | ---679M | ---3.93B | ---- | ---- |
Share of profits of associates | 6.49%2.94B | 10.46%2.01B | 97.45%1.09B | 60.37%3.57B | 38.59%2.76B | 42.54%1.82B | -36.05%550M | 354.35%2.22B | 1,077.51%1.99B | 79.94%1.27B |
Earning before tax | -4.32%71.43B | -11.31%46.39B | -9.42%24.81B | -6.90%92.78B | -10.92%74.65B | -6.15%52.3B | -4.18%27.4B | 26.23%99.65B | 40.64%83.8B | 46.22%55.73B |
Tax | 8.22%-12.45B | 16.58%-7.99B | -5.70%-4.03B | -23.34%-17.58B | -29.46%-13.56B | -54.33%-9.58B | 24.53%-3.81B | 21.50%-14.26B | 2.29%-10.47B | 2.24%-6.21B |
After-tax profit from continuing operations | -3.45%58.98B | -10.13%38.4B | -11.86%20.79B | -11.95%75.19B | -16.69%61.09B | -13.73%42.72B | 0.18%23.59B | 40.49%85.4B | 50.06%73.33B | 55.90%49.52B |
Earning after tax | -3.45%58.98B | -10.13%38.4B | -11.86%20.79B | -11.95%75.19B | -16.69%61.09B | -13.73%42.72B | 0.18%23.59B | 40.49%85.4B | 50.06%73.33B | 55.90%49.52B |
Minority profit | -2.04%8.42B | -4.03%5.63B | 4.09%3.03B | -15.28%10.57B | -18.44%8.59B | -16.61%5.86B | -21.86%2.91B | 33.23%12.47B | 38.83%10.53B | 33.49%7.03B |
Profit attributable to shareholders | -3.68%50.57B | -11.10%32.77B | -14.11%17.76B | -11.38%64.63B | -16.39%52.5B | -13.25%36.86B | 4.32%20.68B | 41.82%72.93B | 52.13%62.79B | 60.35%42.49B |
Basic earnings per share | -3.63%2.546 | -11.11%1.649 | -14.12%0.894 | -11.36%3.253 | -16.39%2.642 | -13.28%1.855 | 4.31%1.041 | 41.81%3.67 | 52.07%3.16 | 60.34%2.139 |
Diluted earnings per share | -14.12%0.894 | -11.36%3.253 | 1.041 | 41.81%3.67 | ||||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | KPMG Huazhen (Special General Partnership), KPMG | -- | -- | -- | KPMG Huazhen (Special General Partnership), KPMG | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.